Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan-Reference-Cited by-同舟云学术

Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan

Published:2011-06 Issue:3 Volume:53 Page:368-373
ISSN:1328-8067
Container-title:Pediatrics International
language:en
Short-container-title:

Author:

Kusuda Satoshi,Takahashi Naoto,Saitoh Takami,Terai Masaru,Kaneda Hisashi,Kato Yuichi,Ohashi Atsushi,Watabe Shinichi,Joh-o Kunitaka,Hirai Katsuki

Publisher

Wiley

Subject

Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1442-200X.2010.03249.x/fullpdf

Reference16 articles.

1. Visiting experts find the “mystery disease” of Naples is a common virus;Marshall;Science,1979

2. Respiratory Syncytial Virus

3. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada;Navas;J. Pediatr.,1992

4. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group;Subramanian;Pediatr. Infect. Dis. J.,1999

5. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV;American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn;Pediatrics,1998

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of the past and present status of respiratory syncytial virus and rotavirus infections that commonly affect children;Journal of Infection and Chemotherapy;2024-09

2. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan;Infectious Diseases and Therapy;2024-06-05

3. A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK ‐1654 in healthy Japanese adults;Clinical and Translational Science;2022-05-17

4. Disease burden of respiratory syncytial virus infection in the pediatric population in Japan;Journal of Infection and Chemotherapy;2022-02

5. Epidemiology of respiratory syncytial virus in Japan: A nationwide claims database analysis;Pediatrics International;2021-12-17